Jesse J. Swen

10.4k total citations · 4 hit papers
164 papers, 5.9k citations indexed

About

Jesse J. Swen is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Oncology. According to data from OpenAlex, Jesse J. Swen has authored 164 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Pharmacology, 42 papers in Pediatrics, Perinatology and Child Health and 42 papers in Oncology. Recurrent topics in Jesse J. Swen's work include Pharmacogenetics and Drug Metabolism (87 papers), Pharmaceutical studies and practices (32 papers) and Renal Transplantation Outcomes and Treatments (17 papers). Jesse J. Swen is often cited by papers focused on Pharmacogenetics and Drug Metabolism (87 papers), Pharmaceutical studies and practices (32 papers) and Renal Transplantation Outcomes and Treatments (17 papers). Jesse J. Swen collaborates with scholars based in Netherlands, United States and Germany. Jesse J. Swen's co-authors include Henk‐Jan Guchelaar, Hans Gelderblom, Andrea Gaedigk, Kelly E. Caudle, Teri E. Klein, Vera H.M. Deneer, Dirk Jan A. R. Moes, Marga Nijenhuis, Ron H. N. van Schaik and Jan van der Weide and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American College of Cardiology and PLoS ONE.

In The Last Decade

Jesse J. Swen

153 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pharmacogenetics: From Bench to Byte— An Update of Guidelines

2011 747 citations Jesse J. Swen, Marga Nijenhuis et al. Clinical Pharmacology & Therapeutics profile →
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

2017 406 citations Jesse J. Swen, Teri E. Klein et al. Clinical Pharmacology & Therapeutics profile →
Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group

2019 369 citations Kelly E. Caudle, Katrin Sangkuhl et al. profile →
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics

2023 71 citations Marga Nijenhuis, Bianca Soree et al. European Journal of Human Genetics profile →

Peers

Countries citing papers authored by Jesse J. Swen

Since Specialization

Citations

This map shows the geographic impact of Jesse J. Swen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jesse J. Swen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jesse J. Swen more than expected).

Fields of papers citing papers by Jesse J. Swen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jesse J. Swen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jesse J. Swen. The network helps show where Jesse J. Swen may publish in the future.

Co-authorship network of co-authors of Jesse J. Swen

This figure shows the co-authorship network connecting the top 25 collaborators of Jesse J. Swen. A scholar is included among the top collaborators of Jesse J. Swen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jesse J. Swen. Jesse J. Swen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long‐Read Sequencing Enhances Pharmacogenomic Profiling by Resolving Complex Haplotypes, Novel Star Alleles, and Structural Variants 2025 ·Clinical Pharmacology & Therapeutics ·(unknown), Andrea Gaedigk, Jesse J. Swen, Henk‐Jan Guchelaar, Shivashankar H. Nagaraj	0
2	Effect of CYP3A4 Methylation on Tacrolimus Pharmacokinetics 2025 ·Therapeutic Drug Monitoring ·(unknown), (unknown), Costanza L. Vallerga, Dirk Jan A. R. Moes, (unknown), Jesse J. Swen, Minneke J. Coenraad, Teun van Gelder	0
3	Implementing Pre‐Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects 2025 ·Clinical Pharmacology & Therapeutics ·(unknown), Eugène T.P. Verwiel, Maaike van der Lee, Jesse J. Swen, (unknown), (unknown), Rick Admiraal, Bastiaan B.J. Tops, Alwin D. R. Huitema, Patrick Kemmeren, Jayne Y. Hehir‐Kwa, Lidwien M. Hanff, (unknown)	1
4	A Comprehensive CYP2D6 Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development 2025 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), (unknown), (unknown), (unknown), Dominik Selzer, Donato Teutonico, (unknown), Juri Solodenko, Sebastian Frechen, Maaike van der Lee, Dirk Jan A. R. Moes, Jesse J. Swen, Matthias Schwab, Thorsten Lehr	3
5	Genetic polymorphisms and major bleeding risk during vitamin K antagonists treatment: The BLEEDS case‐cohort 2024 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·(unknown), (unknown), Mettine H.A. Bos, Pieter H. Reitsma, F.J.M. van der Meer, Jesse J. Swen, Suzanne C. Cannegieter, Nienke van Rein	0
6	Personalized Chronomodulated 5‐Fluorouracil Treatment: A Physiologically‐Based Pharmacokinetic Precision Dosing Approach for Optimizing Cancer Therapy 2024 ·Clinical Pharmacology & Therapeutics ·(unknown), Jan‐Georg Wojtyniak, Dominik Selzer, Robert Dallmann, Jesse J. Swen, Henk‐Jan Guchelaar, Matthias Schwab, Thorsten Lehr	7
7	Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand? 2023 ·British Journal of Clinical Pharmacology ·Elena Peruzzi, Rossana Roncato, Elena De Mattia, Alessia Bignucolo, Jesse J. Swen, Henk‐Jan Guchelaar, Giuseppe Toffoli, Erika Cecchin	8
8	Physiologically‐based pharmacokinetic modeling of quinidine to establish a CYP3A4, P‐gp, and CYP2D6 drug–drug–gene interaction network 2023 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), (unknown), (unknown), Dominik Selzer, (unknown), Donato Teutonico, Sebastian Frechen, Maaike van der Lee, Dirk Jan A. R. Moes, Jesse J. Swen, Matthias Schwab, Thorsten Lehr	9
9	Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users 2023 ·Genes ·Marleen E. Jansen, Tessel Rigter, (unknown), Patrick C. Souverein, W. M. Monique Verschuren, Susanne J. H. Vijverberg, Jesse J. Swen, Wendy Rodenburg, Martina C. Cornel	2
10	Development and Bioequivalence of 3D‐Printed Medication at the Point‐of‐Care: Bridging the Gap Toward Personalized Medicine 2023 ·Clinical Pharmacology & Therapeutics ·(unknown), (unknown), Dina M. Kweekel, Brenda C. M. de Winter, Jesse J. Swen, P.P.H. Le Brun, (unknown), Teun van Gelder, Henk‐Jan Guchelaar, Dirk Jan A. R. Moes, Kirsten J. M. Schimmel	23
11	Increased Tacrolimus Exposure in Kidney Transplant Recipients With COVID-19: Inflammation-Driven Downregulation of Metabolism as a Potential Mechanism 2022 ·Transplant International ·(unknown), Soufian Meziyerh, (unknown), Dirk Jan A. R. Moes, (unknown), Y K Onno Teng, Jesse J. Swen, Aiko P. J. de Vries	4
12	Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data 2021 ·Science Translational Medicine ·Maaike van der Lee, (unknown), Rolf H. A. M. Vossen, Renée Baak-Pablo, Roberta Menafra, Birgit Deiman, Maarten J. Deenen, Patrick Neven, Inger Johansson, Stefano Gastaldello, Magnus Ingelman‐Sundberg, Henk‐Jan Guchelaar, Jesse J. Swen, Seyed Yahya Anvar	45
13	Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study 2021 ·Clinical Pharmacokinetics ·Dirk Jan A. R. Moes, David J. van Westerloo, Sandra M. Arend, Jesse J. Swen, Annick de Vries, Henk‐Jan Guchelaar, Simone A. Joosten, Mark de Boer, Teun van Gelder, Judith van Paassen	10
14	Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs 2021 ·European Journal of Human Genetics ·J. Brouwer, Marga Nijenhuis, Bianca Soree, Henk‐Jan Guchelaar, Jesse J. Swen, Ron H. N. van Schaik, Jan van der Weide, Gerard A. Rongen, Anne‐Marie Buunk, Nienke J. de Boer‐Veger, Elisa J. F. Houwink, Roos van Westrhenen, Bob Wilffert, Vera H.M. Deneer, Hans Mulder	78
15	Using Personal Genomic Data within Primary Care: A Bioinformatics Approach to Pharmacogenomics 2020 ·Genes ·(unknown), (unknown), Andrea W.M. Evers, Johan T. den Dunnen, Marco Roos, (unknown), (unknown), Jesse J. Swen, Mattijs E. Numans, Elisa J. F. Houwink	8
16	Comparison of the Impact of Pharmacogenetic Variability on the PK of Slow Release and Immediate Release Tacrolimus Formulations 2020 ·Genes ·Teun van Gelder, (unknown), Dirk Jan A. R. Moes, Jesse J. Swen	5
17	Development of the PGx‐Passport: A Panel of Actionable Germline Genetic Variants for Pre‐Emptive Pharmacogenetic Testing 2019 ·Clinical Pharmacology & Therapeutics ·Cathelijne H. van der Wouden, (unknown), (unknown), Magnus Ingelman‐Sundberg, Volker M. Lauschke, Lidija Konta, Matthias Schwab, Jesse J. Swen, Henk‐Jan Guchelaar	73
18	Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update 2017 ·Data Archiving and Networked Services (DANS) ·J. Kevin Hicks, Katrin Sangkuhl, Jesse J. Swen, Vicki L. Ellingrod, Daniel J. Müller, Kazutaka Shimoda, Jeffrey R. Bishop, Evan D. Kharasch, Todd C. Skaar, Andrea Gaedigk, Henry M. Dunnenberger, Teri E. Klein, Kelly E. Caudle, Julia Stingl	57
19	[Pharmacogenetics in primary health care: implementation and future expectations]. 2015 ·PubMed ·Elisa J. F. Houwink, Tessel Rigter, Jesse J. Swen, Martina C. Cornel, Anne S. Kienhuis, Wendy Rodenburg, M Weda	3
20	Farmacogenetica in de eerstelijnszorg. Toepassingen en toekomstverwachtingen 2015 ·Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank ·(unknown), (unknown), Jesse J. Swen, Martina C. Cornel, (unknown), (unknown), M Weda	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact